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ABSTRACT 
Insulin Stimulated Lactate Production 
by Jordan Griffin 
 
 It has been shown that Type 2 diabetic patients who undergo Roux-en-Y Gastric 
Bypass surgery (RYGB) show a decrease in muscle lactate production, liver glucose 
production and pancreatic insulin secretion. To explain these changes, it is hypothesized 
that gastric bypass surgery “removes” a block at pyruvate oxidation in both muscle and 
liver. A block at pyruvate oxidation prior to RYGB would cause pyruvate to accumulate 
in the muscle and its only pathway for disposal would be through export as lactate. After 
RYGB, pyruvate dehydrogenase would be activated, allowing pyruvate to be oxidized. 
Thus, lactate would not be exported from the muscle, reducing the availability of this 
gluconeogenic substrate. Elevated lactate levels drive glucose production. The rapid 
remission of diabetes after RYGB is accompanied by a reduction in blood lactate 
concentrations and therefore a reduction in fasting glucose concentration. This study was 
done to compare glucose and lactate levels in subjects 1-3 years post RYGB to age- and 
BMI-matched control subjects. Our hypothesis was that there will be no significant 
differences in glucose and lactate levels in subjects post-RYGB and control subjects, 
suggesting that RYGB causes these levels to return to normal. Each subject underwent an 
intravenous glucose tolerance test and blood samples were taken at baseline and 29 
additional time points over the course of three hours. Each blood sample was analyzed 
for glucose and lactate values and the results between the two groups were compared. 
 Our results show that on average, lactate values in RYGB patients are lower than their 
age- and BMI-matched controls, suggesting that the surgery induces a lasting change in 
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INTRODUCTION 
 
 The obesity epidemic is one that has been no secret in the United States over the 
past decade. Over one third of the entire population of adults in the United States is 
obese. Obesity can lead to countless health problems such as cardiovascular disease, 
which is the leading cause of death in the United States, and Type 2 Diabetes.  
 Type 2 Diabetes is characterized by high glucose levels due to the body’s inability 
to produce and/or utilize insulin. If not taken care of properly, diabetes has the potential 
to cause many complications, including blindness, nerve damage, foot problems, and 
even death. As one of today’s biggest expenses in health care, it is imperative that 
research be done to find a cure for this disease that affects so many.  
 Current research supports the idea that gastric bypass surgery is an effective 
treatment for both obesity and Type 2 Diabetes. However, surgery is costly and opens 
doors for potential complications. In addition, the success of gastric bypass surgery is 
dependent upon the patient’s compliance to diet and exercise regimens as well as 
attending regular post-operative appointments.  
 The purpose of this research is to identify and understand the mechanisms that are 
affected during gastric bypass surgery resulting in the remission of Type 2 Diabetes. If 
these mechanisms can be identified, new medicines can be developed that replicate these 
changes and therefore cure Type 2 Diabetes without surgery.  
 This study specifically looks at the differences in glucose and lactate levels during 
an intravenous glucose tolerance test in subjects who underwent gastric bypass surgery in 
the past 1-3 years and their age- and BMI-matched controls. The glucose and lactate 
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levels will show us if the surgery restores insulin sensitivity to normal for 1-3 years post-
surgery.  
 To explain the mechanism of these changes, it is hypothesized that gastric bypass 
removes a block at pyruvate oxidation in both muscle and liver. A block at pyruvate 
oxidation prior to gastric bypass surgery, and thus in Type 2 diabetics, would cause 
pyruvate to accumulate in the muscle and its only pathway for disposal would be through 
export as lactate. After the surgery, pyruvate dehydrogenase would be activated, allowing 
pyruvate to be oxidized. Thus, lactate would not be exported from the muscle, reducing 
the availability of this gluconeogenic substrate. Taking this mechanism into 
consideration, our hypothesis is that glucose and lactate levels in subjects 1-3 years post-
RYGB will be restored to normal, and thus similar to healthy individuals who have never 
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REVIEW OF LITERATURE 
 
Insulin Action in Skeletal Muscle 
 The hormone insulin has three target tissues in the body: liver, fat, and skeletal 
muscle1. For the purposes of this research we will focus on its role in skeletal muscle and 
how it contributes to the homeostasis of glucose levels in the body as a whole. Skeletal 
muscle is responsible for about 75% of the body’s disposal of glucose2. In normal, 
insulin-sensitive individuals, insulin is secreted from the beta cells of the pancreas in 
response to elevated blood glucose. As a simplified explanation of the complex molecular 
process, the insulin attaches to the “doors” of skeletal muscle cells and opens them, 
allowing glucose into the cell. This reduces the amount of glucose in the blood and 
increases the amount of glucose in skeletal muscle, which then uses this glucose for 
energy. A study by Zierath, et al. referred to this process as “insulin-stimulated glucose 
transport,” while a study by Idris, et al. referred to it as “insulin-mediated glucose 
uptake”1,3. Regardless of its name, this process requiring sensitivity to insulin is essential 
to maintaining appropriate levels of blood glucose and keeping the body at an appropriate 
balance. 
 
Role in Obesity 
 It is widely known that there is a strong relationship between obesity and insulin 
resistance, which subsequently may contribute to the development of Type 2 Diabetes. 
Insulin resistance can be defined as a decrease in insulin-stimulated glucose transport and 
can be caused at the level of insulin signaling in various target tissues and adipocytes. It 
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has been found that in skeletal muscle of obese individuals, the expression of multiple 
insulin signaling molecules is reduced, although the exact mechanisms have not yet been 
discovered4-6. 
 
How Insulin Resistance is altered with Gastric Bypass 
 In a study by Cazzo, et al., the majority of obese, insulin-resistant patients who 
underwent Roux-en-Y Gastric Bypass surgery showed improved insulin resistance and 
decreased fasting glucose within one year after surgery, which is consistent with the 
findings of other comparable studies7-8. This improvement may be the result of altered 
secretion of gastrointestinal peptides in combination with weight loss9 but conclusive 

















 This study compared two different subject groups. The experimental group, also 
referred to as Group B, consisted of Caucasian females ages 31-58 that had undergone 
Roux-en-Y Gastric Bypass surgery within the past 1-3 years, were currently weight-
stable and were apparently healthy. Potential subjects for this group were found in Vidant 
Medical Center and ECU Physicians’ Electronic Health Record system. The potential 
subjects were contacted and informed about the study and its requirements.  
Subjects for the control group, also referred to as Group N, consisted of Caucasian 
females ages 30-53 that had never had any type of weight loss procedure, were weight-
stable and were apparently healthy. To recruit these subjects flyers were posted around 
the community of Greenville in addition to a mass e-mail sent to all East Carolina 
University faculty and staff. Interested subjects were told to contact a researcher for more 
information. 
 If the potential subjects chose to participate it was verified that they met all 
inclusion criteria and prior to beginning the study they signed a consent form as well as a 
UMCIRB HIPAA Privacy Authorization form. Subjects were compensated $100 for their 
time and travel. A total of 10 subjects for group B and 7 subjects for group N completed 
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Protocol 
 All subjects underwent a minimal model intravenous glucose tolerance test under 
specific protocol. Upon arrival, the subject’s weight was obtained after voiding. The 
weight was used to determine the amount of glucose and insulin to be administered 
during the minimal model with the following formulas: 
 Glucose: mls of 50% solution of glucose = body mass (kg) X 0.3g X 2 
 Insulin:  body mass (kg) X 0.025 U 
A catheter at least 20 gauge was inserted into the brachiocephalic vein. In ideal 
conditions, one IV was started in each arm of the subject so that one arm was used for 
drug administration and one arm was used for lab draws. In some cases this was not 
realistic due to bad veins or poor blood flow. In all cases, however, two different IV’s 
were used to administer drugs and draw blood. 40 cc of blood were drawn prior to the 
administration of glucose for the performance of baseline lab assays. The calculated 
amount of 50% glucose solution was administered over one minute. Lab draws began at 2 
minutes after the glucose administration and were repeated at minutes 3, 4, 5, 6, 8, 10, 12, 
14, 16, and 19. At 20 minutes, the calculated dose of U-10 regular insulin was 
administered over one minute. 2 cc’s of blood were then drawn at the following time 
points: 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, and 180 minutes. 
 After each lab draw, 1.5 mL of whole blood was immediately and gently 
transferred into a gray top tube (used for glucose and lactate analysis) using a P1000 
pipette. The cap was secured and the tube was inverted 8 times and stored on ice. The 
remaining blood was then transferred into a purple top tube (used for insulin analysis) 
and the appropriate volume of protease inhibitor cocktail was immediately added 
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depending on the volume of blood in the tube. The cap was secured and the tube was 
inverted 5 times and stored on ice. Every 15 minutes, all tubes were centrifuged at 2500 
rpm for 12 minutes at 4 degrees Celsius. After spinning, 300 microliters of the plasmas 
were aliquoted into cryovials (3 cryovials for each time point) and were immediately 
placed into a freezer at -80 degrees Celsius where they remained until the data analysis. 
 
Data Analysis 
 The plasma from the gray top tubes was analyzed for glucose and lactate values at 
each time point using the Beckman Coulter UniCel DxC 600i. The results were then 
analyzed using various methods including t-tests, area under the curve analysis, and 
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RESULTS 
 





Figure 2. Net Glucose Area Under the Curve 
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The glucose values and area under the curve analysis show that the surgery group (group 
B) has slightly higher glucose values throughout the duration of the glucose tolerance test 
and thus, a greater area under the curve. 
 
Figure 3. Lactate vs. Time 
 
 
Figure 4. Net Lactate Area Under the Curve 
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The lactate values and area under the curve analysis show that the surgery group (group 
B) have lower lactate values throughout the duration of the glucose tolerance test and 
thus, a smaller area under the curve. 
 
Figure 5. Lactate Area Under the Curve Above Baseline  
 
 
Figure 6. Lactate Area Under the Curve Below Baseline 
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These graphs show the area under the curve analysis for lactate both above baseline and 
below baseline. Above baseline, the surgery group (group B) has a smaller area under the 
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DISCUSSION 
 
 At fasting, glucose levels in both the surgery group (group B) and the non-surgery 
group (group N) are stable. This means that glucose production is equal to glucose 
utilization. Throughout the glucose tolerance test, the relative stability of glucose levels 
in both groups indicates that both groups utilize glucose at the rate that it is produced. For 
lactate, however, both groups show a rise in lactate levels followed by decrease to 
baseline in group N and below baseline in group B. The area under the curve above 
baseline shows that group N produces more lactate than group B. The area under the 
curve below baseline shows that group B utilizes more lactate than group N. This excess 
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CONCLUSION 
 
 These results are consistent with what is seen in RYGB patients one week after 
surgery, suggesting that the lactate-producing mechanism that is altered during the 
surgery is still effective 1-3 years post-surgery. In comparison with our hypothesis that 
lactate levels in RYGB patients 1-3 years post-surgery would be similar to healthy 
individuals, the results show that the surgery has a lasting effect that improves pyruvate 
oxidation to the point where it is even more effective than that of healthy individuals. 
This supports the idea that improved pyruvate oxidation as a result of gastric bypass 
surgery is one of the mechanisms contributing to the remission of Type 2 Diabetes. To 
further this research, other mechanisms altered during RYGB should be investigated to 
determine which alterations contribute to the remission of Type 2 Diabetes and should 
therefore be considered during the development of medicines to cure the disease. 
Additionally, more longitudinal studies should be done to further verify conclusions from 
this study as well as examine factors contributing to the long-term success or failure of 
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APPENDIX C 
 




The Bariatric Surgery Research Group at East Carolina University (Brody School 
of Medicine) is conducting a research study to better understand diabetes.  
	   
If you are a Caucasian woman 40-55 years of age, with a BMI ranging from 22 to 
32, at a stable weight, and have never had a weight loss surgery procedure, 
please call our research coordinator for more information.  
	   




Jordan Griffin: griffinj11@students.ecu.edu;  
252-813-4860 
 
